|
|
 |
 |
| |
 Printable version |
Modulation of apoptosis : a therapeutic objective for the future : arsenic trioxide, a progress to treat the acute promyelocytic leukemia |
Journal de Pharmacie Clinique. Volume 19, Number 2, 108-14, Juin 2000, Pharmacothérapie
|
 Résumé
Article gratuit
|
Author(s) : J.-J. Houri, V. Acar, D. Pradeau, F. Guyon |
Summary : Apoptosis is required for the maintenance of cellular homeostasis. This programmed cell death, triggered and controlled by a wide variety of exogenous and endogenous stimuli, leads to the activation of the family of cysteine proteases so-called caspases, inducing the apoptotic process. The list of pathologies related to abnormal regulation of apoptosis is increasing. The understanding of the mechanisms involved in this cell death allows us to detect potential new targets. They may lead to new therapeutic strategies, either activating or inhibiting the apoptotic process.
Arsenic trioxide used in treatment of acute promyelocytic leukemia induces apoptosis. Indeed, Chinese and American teams have shown that inorganic arsenic trioxide can induce complete remission in patients. Although mechanisms underlying arsenic to induce apoptosis are not yet well known, the clinical response to this treatment is linked to activation of caspases. These encouraging results have led the Assistance Publique-Hôpitaux de Paris to develop a phase II clinical trial of arsenic trioxide in five kinds of refractory hemopathies. |
Keywords : poptosis, arsenic trioxide, acute promyelocytic leukemia. |
|
